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Abstract
One out of 10 cancers is estimated to arise from infections by a handful of oncogenic viruses. These
infectious cancers constitute an opportunity for primary prevention through immunization against the
viral infection, for early screening through molecular detection of the infectious agent, and potentially
for specific treatments, by targeting the virus as a marker of cancer cells. Accomplishing these objectives
will require a detailed understanding of the natural history of infections, the mechanisms by which the
viruses contribute to disease, the mutual adaptation of viruses and hosts, and the possible viral evolution
in the absence and in the presence of the public health interventions conceived to target them. This
issue showcases the current developments in experimental tissue-like and animal systems, mathematical
models and evolutionary approaches to understand DNA oncoviruses. Our global aim is to provide
proximate explanations to the present-day interface and interactions between virus and host, as well
as ultimate explanations about the adaptive value of these interactions and about the evolutionary
pathways that have led to the current malignant phenotype of oncoviral infections.
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1 DNA oncoviruses: low infec-
tion virulence and high disease
burden
Certain infections can cause cancers in humans,
and indeed between 15% and 20% of all cancers
in humans have a direct infectious origin. Some
of the most oncogenic biological agents to humans
are a handful of DNA viruses. In 2012, cancers
caused by these DNA viruses represented 56% of
the 2.2 million new cases of cancers attributed to
infectious agents. This proportion was even higher
(> 80%) in regions of the world with low Human
Development Index [12, 28]. Thus, cancers caused
by DNA oncoviruses impose a substantial disease
burden that becomes greater in developing coun-
tries. The human morbidity linked to the asso-
ciated diseases makes DNA oncoviruses a major
public health concern. This medical importance
has resulted in a substantial body of fundamental
research leading to the discovery of the different
viruses, to a detailed description of the virocellular
interactions and to their identification as oncogenic
biological agents to humans (we will hereafter refer
to “virocell” as the metabolically active vegetative
stage in the viral life cycle [18]). In a few cases,
applied research has led to development of diagnos-
tic, therapeutic and even prophylactic approaches
for these viral infections. Oncogenic human papil-
lomaviruses (HPVs) and anogenital cancers serve
as paradigmatic example of this successful story,
from the early identification of cervical cancer epi-
demiology to match that of sexually transmitted
infections, to the development of prophylactic vac-
cines against the most oncogenic HPVs [13]. Yet,
for the vast majority of oncogenic DNA viruses we
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still know relatively little about how these viruses
enter, manipulate and take over the infected cell,
how they interact with the host’s immune system
during the acute and the chronic phases of the in-
fection, how they maintain intra-host and popula-
tion diversity, and how the viral populations may
respond to the public health interventions imple-
mented to tackle these infections. Ultimately, for
all oncogenic DNA viruses, we still ignore why
these highly prevalent infections are largely asymp-
tomatic, yet in a small fraction of the cases they
can progress to malignancies.
The socioeconomic burden caused by DNA on-
covirus infections does not arise from a high mor-
tality rate among the infected persons, but rather
from the extremely high prevalence of these infec-
tions. For most DNA oncoviruses, the accumu-
lated probability for a human to have ever been in-
fected during lifetime approaches one, i.e. at some
point in their lives virtually all humans will have
been infected by some oncogenic papillomavirus,
polyomavirus or herpesvirus. On the other hand,
most of these infections are asymptomatic or clin-
ically irrelevant, and only a small fraction leads
eventually to a cancer. Taking the best-known case
of oncogenic HPVs, the prevalence of cervical infec-
tion in women below 25 years of age is 29.7%, while
the world average cumulative risk at 75 years old
for a woman to develop cervical cancer is 1.36%
(data extracted from the HPV information cen-
tre, https://www.hpvcentre.net [7]). This sharp
contrast between high prevalence and low morbid-
ity generates a situation that may appear confus-
ing to the general public, since at the individual
level the risk of developing cancer following an in-
fection is low, but at the population level the cu-
mulative burden is high. This low virulence per in-
fection is a key feature of the problem. First, as for
any rare event, the potential role of stochasticity is
high. This has been exemplified in the case of HPV
infections to explain why some lesions regress nat-
urally and other do not [31], or in the case of her-
pesvirus infections to explain the role of asymmet-
ric segregation of viral genomes during cell division
[10]. Second, virulence is always the result of the
interaction between the virus genotype, the host
genotype and their “environment”. This tripartite
interplay is referred to as G*G*E interactions in
ecology and evolution, while epidemiologists often
pinpoint individual edges in this interaction net-
work and refer to them as co-factors. Third, the
notion of “environment” for a viral infection must
be understood as a Russian-doll hierarchical inte-
gration across levels, from the virocell to the ecol-
ogy: cell type diversity may display different per-
missivity to the infection and different potential
for malignisation (in the case of HPV, see [20]); tis-
sue diversity may differentially foster malignancy
[22]; organ diversity may introduce within-patient
spatial structuring of the viral population [4]; indi-
vidual behaviour may strongly impact viral circu-
lation; biological and physicochemical agents may
modify the host-pathogen interaction; and human
population structure will undoubtedly pattern vi-
ral population structure. In summary, to under-
stand DNA oncovirus virulence, it is necessary to
adopt a multi-scale approach and bridge the cellu-
lar and the population levels.
2 The challenge of defining a
common playground: from
molecules to ecology, from
research protocols to clinical
guidelines and public health in-
terventions
The questions raised by oncogenic DNA viruses de-
mand responses from the microscopic, molecular
dimension to the macroscopic, ecological dimen-
sion. The need to integrate so many levels for un-
derstanding the multidimensional problem of in-
fectious cancers is often hindered by the lack of a
shared scientific culture: the burden of proof is dif-
ferent in experimental and modelling approaches;
the number of degrees of freedom, and thus the
strength of any inferred association, is different in
in vitro techniques and in epidemiology; a deeper
understanding of the underlying evolutionary pro-
cesses may not necessarily bring along an imme-
diate impact in cancer treatment; difficult clini-
cal decisions must often be taken using partial in-
formation and resorting to phenomenon-directed
knowledge, without the option to wait for a future
better understanding of the molecular basis of the
disease. The framework summarised by Nikolaas
Tinbergen [33] to assemble research approaches
and comprehension levels is a powerful intellectual
tool to conceptualise, build and share knowledge
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across fields (Table 1). It may help us succeed in
building a common understanding and creating a
shared perspective for scientists with largely diver-
gent conceptions of science.
From a practical side, bringing together fields
that study the same entity from different perspec-
tives can directly help researchers, e.g. by using
techniques and borrowing concepts as inspiration.
But the potential for this dialogue for DNA on-
coviruses is even bigger because we are currently
witnessing advances in different fields, from tissue-
like cell cultures to deep sequencing, that make
cross-fertilization between fields extremely valu-
able, as illustrated already by some pioneering re-
search. For instance, mathematical modelling can
be a means to infer biological quantities that are
difficult to measure. This is routinely done in epi-
demiology and also for rapidly-evolving viruses,
such as human immunodeficiency virus or hepatitis
C virus [9], but still rarely applied to the virocel-
lular and within-host level for oncogenic viruses
by analysing viral and immunological data [19].
Such exchange between disciplines and approaches
addressing either proximate or ultimate explana-
tions is common. The challenge is to build a fer-
tile dialogue between unveiling mechanisms and
identify adaptations; between describing the nat-
ural history of the disease and understanding the
therein-intertwined evolutionary histories of hosts
and pathogens. Indeed, evolutionary analyses on
ultimate causes can shed new light on to proximate
causes at the tissue level and suggest new hypothe-
ses to test, such as the study of within-cancer het-
erogeneity [8, 1]. Conversely, a better understand-
ing of the natural history of the infections and dis-
eases, as well as of the virus-host interactions at
the cell and organismic level will guide research on
the evolution of DNA viruses and their virulence.
A promising example in this direction, is how ac-
counting for the well-known latency periods and
transmission patterns shifts during varicella zoster
virus infections in the evolutionary models strongly
modifies our understanding of the evolution, origin
and spread of the virus [36]. In summary, address-
ing the infections and diseases caused by DNA on-
coviruses with an integrated, multilevel approach
is needed, is timely and can represent an inspira-
tion for other infectious diseases.
For all oncoviruses, spatial and time scales are
important. Some of these viruses cause systemic
infections while others are tissue-restricted, but
in both cases the local spatial structure strongly
shapes their infection fitness. Also, in most cases
DNA oncoviruses establish very long relationships
with their hosts, leading to chronic infections punc-
tuated by episodes of reactivation [35]. The vi-
rocellular activity during the latent or the silent
phases of the chronic infection sharply differs from
that in the acute phase, even for viruses with small
genomes and limited coding potential, and the po-
tential for malignancy strongly depends on the cel-
lular genomic changes associated to this chronic
infection. Bridging spatio-temporal scales seems
necessary for at least three levels. First, an indi-
vidual cell may acquire (epi)genotypic or pheno-
typic mutations allowing barriers and restraints to
malignancy to be overcome, but cancer is not an
unicellular event. It is instead an organic event
in which the cancerous lineages compete to spread
through population processes, but whose success
is strongly dependent on the necessary coopera-
tion of non-cancerous cells. Second, because each
virion can only infect a single cell, every individ-
ual infection is always eventually a dead end from
the virus’ point of view, and this is clearer in in-
fection driven cancers, in which the transformed
cells may not produce any viral particles. Virion
production and transmission is the only key to vi-
ral persistence, which necessarily links within-host
and between-host dynamics. Finally, viral evolu-
tion is perhaps the most obvious multi-scale pro-
cess: it takes its roots in biochemical mutational
stochastic events, while its dynamics are governed
by epidemic spread first within the infected host
and then in the human population.
DNA oncoviruses have more in common than
just causing cancers. Historically, their study has
faced a variety of obstacles, whatever the field of
research. For biologists, the scarcity of animal
and tissue-based models has limited the poten-
tial for experimental studies. For epidemiologists,
the sharp contrast between the highly prevalent
asymptomatic infections and the far lower inci-
dence of virus-driven cancers has required epidemi-
ological approaches to enrol large cohorts, so that
significant effects could be detected. For evolu-
tionary biologists, the difficulty to estimate sub-
stitution rates [17] and to disentangle within-host
and between-host dynamics has left plenty of room
for speculation and for the “conventional wisdom”
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Table 1: The Tinbergen conceptual framework for structuring biological questions, applied to the case
of oncogenic DNA viruses. We illustrate it with the example of the E6 protein from oncogenic Alpha-
papillomaviruses, which interacts with and promotes degradation of the human tumour supressor p53
protein.
Contemporary, syn-
chronic perspective
Historic, diachronic perspective
Proximate explanations Mechanisms, function Natural history of the infection, ontogeny
Host-parasite interactions and
their functions at the molecu-
lar, virocellular, organism and
population levels
The connection between the viral and the
host genotypes and the clinical, pheno-
typic presentation of the infection, inte-
grating the interactions with the environ-
ment.
The E6-p53 example Mechanisms, function Natural history of the infection, ontogeny
The E6 protein interacts with
E6AP through a leucine rich
domain and induces p53 bind-
ing polyubiquitination and
proteasomal degradation.
E6 is expressed in the early stages of the
infection in the parabasal and middle ep-
ithelial cell layer, driving cell proliferation,
and stimulating cell cycle re-entry in the
suprabasal epithelial layers.
Ultimate explanations Adaptation Evolution
The problem that a structure
solves, and the adaptive value
conferred by this evolutionary
solution.
The history of genotypic changes in the
host and in the parasite through gen-
erations, resulting in the current host-
parasite interaction phenotype.
The E6-p53 example Adaptation Evolution
Degradation of p53 overcomes
a stringent cellular checkpoint
control that blocks cell divi-
sion and limits viral replica-
tion. The abnormally repli-
cating cell may in its turn ac-
cumulate genomic defects that
may eventually lead to cancer.
The gain-of-function of the E6 oncoprotein
is specific to the clade of oncogenic HPVs
and concurred with an adaptive radiation
event triggered by the integration of a
proto-E5 oncogene in the viral genome.
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that these viruses strictly coevolve with their hu-
man host. For oncologists, it is not necessarily ap-
parent that cancers in a single anatomical location
can be different clinical entities depending on the
viral etiology [2]. For comparative pathologists, it
may be difficult to recognise that distantly related
viruses can cause cancers in the same anatomical
location by analogous but not homologous mecha-
nisms [32]. Finally, as a significant side effect, the
emphasis on cancer has potentially neglected many
other clinical implications of the chronic viral in-
fections, such as effects on fertility or even poten-
tial mutualistic effect [29]. These similarities call
for an effort to join forces between experts work-
ing on different oncoviruses and also from experts
working in different fields. This is the goal of this
special issue, which spans from the virocellular to
the epidemiological level.
3 Focus of the special issue
This issue brings together expertise and insights
from a variety of fields to tackle the threat posed
by oncogenic DNA viruses. The individual contri-
butions aim at providing a timely overview of spe-
cific novel model developments, the ensemble ad-
dressing several integration levels and approaches,
as follows:
• Tissue models: how developments in three-
dimensional cell culture, microfluidics and
other experimental set-ups are improving our
ability to study the interaction between DNA
oncoviruses and their host cells, and between
the virocells and the tissue environment.
• Within-host models: how the combination of
animal models, clinical virology and mathe-
matical modelling allows us to unveil infec-
tion dynamics
• Epidemiological models: how modelling and
understanding human population-level pro-
cesses can provide biologically relevant in-
sights.
• Evolutionary models: how the reconstruction
of evolutionary dynamics can provide hints
to guide fundamental and clinical research.
Because historical contingency is central to un-
derstand the present, also in DNA oncovirus re-
search, the contribution by Daniel DiMaio [14] il-
lustrates the origins and historical twists of the
research on HPVs and cervical cancer. This text
showcases how the technical and conceptual ad-
vances conceived for understanding a particular
cancer have resulted in a successful story with the
identification of cytopathic changes in the infected
cells that allow for early diagnosis, the discovery
of the viral agent causing the disease, and the de-
velopment of a safe vaccine that prevents infection
by the main oncogenic HPVs.
A number of contributions in this issue ad-
dress proximate explanations for specific questions
on virocellular mechanisms and functions: i) Evri-
pioti and coworkers [15] identify cellular signalling
routes converging on cyclic-AMP that seem to me-
diate hepatitis B virus entry in human cells; ii) the
need of developing novel models that bridge be-
tween the classical in vitro cell culture and the in
vivo animal experimentation is illustrated by the
contribution from Jackson and coworkers [21], de-
scribing the in vitro engineering of pseudo-organs
including keratinocytes and Langerhans cells to
study the interaction between oncogenic HPVs
and the immune system; iii) going at the in toto
level, McHugh and coworkers [24] review the re-
cently available humanised mice as a tool to facil-
itate the study of infections by human herpesvirus
4 (Epstein-Barr virus) and human herpesvirus 8
(Kaposi sarcoma-associated herpesvirus); iv) at
the within-host level, McIlroy and coworkers [25]
describe the accumulation of mutations in the
genome of oncogenic polyomaviruses that are asso-
ciated to malignant potential and that are virtually
never found among circulating isolates of the same
viruses; v) finally, also at the sequence level but
focusing on changes in circulating viruses, Bridges
and coworkers [5] present the connection between
polymorphisms in the Epstein-Barr virus genome
and the geographical distribution of viral isolates,
as well as their differential potential for cellular
transformation.
Several exciting contributions in the issue de-
scribe the state-of-the-art for a number of models
addressing proximate explanations for the natural
history of the disease. This is the case of i) the
manuscript by Tomassino and coworkers [34] where
the authors propose that the long-searched mech-
anisms for malignisation by possibly oncogenic cu-
taneous HPVs are analogous rather than homolo-
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gous to those well established and present in onco-
genic mucosal HPVs; ii) seroprevalence data have
been collected over decades for many DNA on-
coviruses, and often regarded as static descriptors
of viral exposure, but two contributions in the is-
sue describe novel mathematical approaches that
exploit within-host antibody titre evolution after
cancer treatment (Piontek and coworkers [27]) and
population-level analyses of antibody titre dynam-
ics that reconcile DNA-based and antibody-based
prevalence of oncogenic HPV infections (Brower
and coworkers [6]); iii) beyond the iconic exam-
ple of cervical cancer, Roberts and coworkers [30]
present the current knowledge on the infection of
lymphoid tissue in the oropharynx by oncogenic
HPVs and the differential mechanisms that may
underlie the malignisation process in this anatom-
ical location, a particular cancer that displays a
rapidly changing and not totally understood epi-
demiology; finally iv) Cladel and coworkers [11]
summarise in their contribution the wealth of in-
formation gained in the last years with the use
of a rabbit papillomavirus animal model devel-
oped in their laboratory that provides intriguing
results about the differences in the clinical phe-
notype caused by infection with viruses carrying
synonymous but largely-recoded genomes.
The study of ultimate explanations on the func-
tional adaptive value is a stimulating but delicate
subject because there is always a risk to venture
too far away from the (limited) data. In this is-
sue, i) Murall and Alizon [26] analyse the evolu-
tionary trade-offs associated to the viral oncopro-
tein functions that on the one hand promote viral
replication by stimulating cellular replication, but
that on the other hand may decrease viral fitness
by facilitating immune targeting or by leading to a
dead-end of a cancer. Further, ii) Ewald and Ewald
[16] elaborate on the possibility that many other
cancers could also be of infectious origin, revisiting
the adage of Francisco Duran-Reynals in early last
century, when saying that failure to demonstrate
infectious virus in a tumour does not mean that a
virus was not involved [3], and claiming that the
roles of the cellular stroma and the immune system
may prevent the identification of the viral onco-
genic agent in the invasive, mature presentation of
the cancer.
Finally two articles of the issue address the
evolutionary, ultimate explanations of the cancer-
ous phenotype by oncogenic DNA virus infections:
i) Man and coworkers [23] introduce an original
approach to enable predictions into the scientific
hottest debate around vaccination against onco-
genic HPV, namely the so-called type-replacement
problem, which refers to the possibility that viral
lineages not targeted by the vaccines could increase
in prevalence and occupy the empty niche left by
the targeted ones, provided the different HPVs are
actually establishing competitive interactions. Fi-
nally, ii) Willemsen and Bravo [37] have addressed
the reconstruction of the evolutionary history of
the papillomaviruses, identifying the common ori-
gin of the E6 and E7 powerful oncogenes and the
acquisition of their transforming activities. In-
triguingly, the authors show that the enhanced
oncogenicity of HPV16, the strongest biological
oncogenic agent to humans, is not linked to the
strength of the E6 activity on p53, which is of-
ten regarded as the epitome of a viral oncoprotein
function.
4 Future steps
We are now witnessing the glorious era of omic
biologic research. It had never been so easy and
inexpensive to generate (meta|epi)genomes, tran-
scriptomes, proteomes and metabolomes, with im-
provements ongoing. Transforming this wealth of
data into information has become rather the limit-
ing factor, in terms of using appropriate hardware
and informatics tools, and in the lack of sound sta-
tistical approaches to define and test competing
hypotheses for this large volume of data and ill-
defined categories and redundancies. As all other
biologic disciplines, research on DNA oncoviruses
and the diseases they cause have bloomed in the
last years, generating massive full-sequence sets for
large human cohorts that have refined some hy-
potheses and refuted others, identified specific sig-
natures of infection-driven cancers and led to dif-
ferential treatment as a function of the viral etiol-
ogy of cancer. The obvious sentences in the “future
directions” section for any scientific field cannot
but adhere to the Olympic motto of citius, altius,
fortius: more and larger natural history studies to
understand within-host ecology; larger cohorts to
understand where these viruses stand on the mu-
tualist–parasite continuum; more sequence data,
which can be made possible with the decreased cost
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of sequencing combined with techniques to enrich
samples in target DNA. We would like neverthe-
less to emphasise again the need of maintaining
the guide of a philosophical explanatory framework
for constructing science, stimulating questions, for-
mulating hypothesis, designing experiments to test
them, and validating the explanatory potential and
scope of our answers. We will be able to claim
that we have an explanation to the existence of
the diversity of DNA oncoviruses and of the associ-
ated diseases they cause only when we understand
why natural selection has not rendered us resis-
tant to oncoviral infection and/or to the disease
development, why not all humans display similar
susceptibility, why very closely related viruses dis-
play very different oncogenic potential, or why we
do not know any animal equivalent to most of the
infection driven cancers in humans.
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